Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $85.74 -1.41%
EPS Growth %: +4.8%
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
CRMT, PKE, HELE, More
EPS Growth %: +4.8%
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
- First Majestic raises 2026 output guidance after Q2 silver, gold gains
- PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
